PMGC Holdings (ELAB) Common Equity (2022 - 2025)
PMGC Holdings (ELAB) posted Common Equity of $7.8 million for Q4 2025, down 13.39% sequentially from $9.0 million in Q2 2025, and up 17.69% YoY from $6.7 million in Q4 2024.
PMGC Holdings (ELAB) Common Equity (2022 - 2025) Analysis & Trends
PMGC Holdings has reported Common Equity for 4 years, with the latest figure at $7.8 million in Q4 2025.
- Quarterly Common Equity rose 17.69% year-over-year to $7.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.8 million (up 17.69% YoY) and the FY2025 annual result came in at $7.8 million, up 17.69% from the prior year.
- Common Equity fell to $7.8 million in Q4 2025 per ELAB's latest filing, from $9.0 million in the prior quarter.
- Over five years, Common Equity peaked at $1.6 billion in Q3 2022 and troughed at -$163895.0 in Q3 2023.
- A 4-year average of $128.5 million and a median of $3.8 million in 2023 frame the typical range for Common Equity.
- The sharpest annual moves came in 2023 and 2024: Common Equity slumped 100.01% in 2023, then surged 5319.94% in 2024.
- Over 4 years, Common Equity stood at $1.1 million in 2022, then soared by 238.29% to $3.8 million in 2023, then jumped by 74.01% to $6.7 million in 2024, then climbed by 17.69% to $7.8 million in 2025.
- According to Business Quant data, Common Equity over the past three periods registered $7.8 million, $9.0 million, and $8.1 million for Q4 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 9.79 Bn |
| 10 | PMGC Holdings | 31.48 Mn | 12.69 Mn | 385,691.00 | 16.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.84 Mn |
| Jun 30, 2025 | 9.05 Mn |
| Mar 31, 2025 | 8.13 Mn |
| Dec 31, 2024 | 6.66 Mn |
| Sep 30, 2024 | 8.56 Mn |
| Jun 30, 2024 | 2.64 Mn |
| Mar 31, 2024 | 2.49 Mn |
| Dec 31, 2023 | 3.83 Mn |
| Sep 30, 2023 | -163,895.00 |
| Jun 30, 2023 | 67,288.00 |
| Mar 31, 2023 | 913,388.00 |
| Dec 31, 2022 | 1.13 Mn |
| Sep 30, 2022 | 1.62 Bn |